Date: July 31, 2026

General Company Information

Corporate Identification: CIN: L24239TG1978PLC002276

Incorporation Year: 1978

Corporate Office: Plot No.11 & 84, TSIIC, Phase-IV, Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad, Telangana - 502 307, India

Contact: Email: investors@glandpharma.com, Tel: +91-8455-699999

Financial Year: April 1, 2025 to March 31, 2026

Stock Exchanges: National Stock Exchange of India Limited, BSE Limited

Paid-up Capital: ₹164,756,423 (divided into 164,756,423 equity shares of ₹1 each)

Reporting Boundary: All disclosures in this BRSR Report are on Standalone basis, unless otherwise mentioned

Business Activities

Primary Business: Pharmaceuticals - Pharmaceutical research and development, manufacturing, and marketing of complex injectables

Turnover Contribution: 100% from development, manufacturing and sale of Generic Formulations (NIC Code: 21009)

Customer Focus: Specializes in sterile injectables, Oncology, and Ophthalmics with focus on complex injectables, NCE-1s, First-to-File products, and 505(b)(2) filings. Operates primarily on B2B model.

Operations Overview

Operational Locations:

  • National: 6 plants + 1 office (includes Corporate and R&D Office) = 7 locations
  • International: 4 plants + 3 offices = 7 locations (subsidiaries)

Markets Served:

  • National: 20 States
  • International: 60 Countries

Export Contribution: 88.44% of total turnover

Employee Statistics (as of March 31, 2026)

Permanent Employees: 4,295

  • Male: 3,764 (88%)
  • Female: 531 (12%)

Permanent Workers: 37

  • Male: 21 (57%)
  • Female: 16 (43%)

Differently Abled: 0 employees and 0 workers

Gender Representation:

  • Board of Directors: 2 females out of 8 members (25%)
  • Key Management Personnel: 0 females out of 4 members (0%)

Turnover Rates (FY2026):

  • Permanent Employees: 14% overall (Male: 14%, Female: 15%)
  • Permanent Workers: 3% overall (Male: 0%, Female: 6%)

Subsidiary Companies

1. Fosun Pharma Industrial Pte. Ltd - Holding Company (51.83% shares)

2. Gland Pharma International Pte Ltd - Wholly owned Subsidiary

3. Gland Pharma USA Inc. - Wholly owned Step-down subsidiary

4. Phixen SAS and its subsidiaries (Cenexi Group) - Wholly owned Step-down subsidiary (100% stake through merger effective January 01, 2025)

CSR Applicability

CSR Applicable: Yes

Turnover: ₹45,520.92 Mn

Net Worth: ₹1,08,100.33 Mn

Material Issues Identified

1. Occupational health and safety (Risk) - Implemented ISO 45001 aligned management system with HIRA and incident reporting

2. Community engagement (Opportunity) - Building trust with local communities

3. Regulatory Compliance (Risk) - Monitoring regulatory changes through government and industry bodies

4. Promoting Diversity (Opportunity) - Fostering diverse and inclusive workforce

5. Cultural Integration (Opportunity) - Integrating subsidiaries across global operations

6. ESG Factors (Risk) - Working to achieve set ESG targets with dedicated timelines

Key Performance Data

Energy Consumption (FY2026):

  • Total energy consumed: 59,38,91,628.25 MJ
  • Renewable energy: 9.236% of total consumption
  • Energy intensity: 13,046.56 per rupee of turnover

Water Management (FY2026):

  • Total water withdrawal: 5,64,312.66 KL
  • Total water consumption: 5,13,659.48 KL
  • Water intensity: 11.28 per rupee of turnover
  • Zero Liquid Discharge implemented at Pashamylaram Facility

GHG Emissions (FY2026):

  • Scope 1: 29,428.09 MT CO2e
  • Scope 2 (Location based): 65,742.42 MT CO2e
  • Scope 2 (Market based): 57,801.26 MT CO2e
  • Emission intensity: 1.92 per rupee of turnover (market based)

Waste Management (FY2026):

  • Total waste generated: 3,223.79 MT
  • Waste recovered: 2,969.85 MT (Recycled: 1,013.36 MT, Re-used: 1,956.49 MT)
  • Waste disposed: 250.25 MT (Incineration: 146.73 MT, Landfilling: 103.52 MT)
  • Waste intensity: 0.07 per rupee of turnover

Employee Wellbeing:

  • Spending on wellbeing measures: 0.16% of total revenue
  • Health insurance coverage: 100% for employees and workers
  • Safety performance: Zero lost time injuries, fatalities, or high consequence injuries

Gender Diversity:

  • Gross wages paid to females: 8.36% of total wages
  • POSH complaints: 2 reported, 2 upheld (0.36% of female employees/workers)

Inclusive Development:

  • Inputs from MSMEs/small producers: 16.92% of total purchases
  • Inputs from within India: 33.04% of total purchases
  • Job creation in rural areas: 53.05% of total wage cost

Openness of Business:

  • Accounts payable days: 67 days
  • Purchases from trading houses: 18% of total purchases
  • Sales to dealers/distributors: 1.27% of total sales
  • Related party transactions: Purchases 5.69%, Sales 8.76%, Investments 100%

Assurance Statement

Assurance Provider: DNV Business Assurance India Private Limited

Assurance Type: Reasonable Level of Assurance

Scope: BRSR Core indicators for FY 2025-26 on standalone basis covering 6 manufacturing units and 1 office in India

Conclusion: BRSR Core KPIs under 9 ESG attributes are reported in accordance with reporting requirements

Governance Structure

Highest Authority for BRSR: Mr. Srinivas Sadu, Executive Chairman (DIN: 06900659)

CSR Committee: Dedicated committee comprising two Non-Executive Directors and One Executive Director, chaired by Mr. Srinivas Sadu

Contact for BRSR Queries: Sampath Kumar Pallerlamudi, Company Secretary and Compliance Officer